| URN | urn:agi-llid:5054 |
|---|---|
| Total Entities | 0 |
| Connectivity | 3249 |
| Name | Serpine1 |
| Description | serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
| Notes | This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009] |
| GO Molecular Function | peptidase inhibitor activity |
|---|---|
| serine-type endopeptidase inhibitor activity | |
| receptor binding | |
| protease binding |
| GO Cellular Component | extracellular matrix |
|---|---|
| extracellular region | |
| platelet alpha granule lumen | |
| plasma membrane | |
| extracellular space |
| GO Biological Process | positive regulation of monocyte chemotaxis |
|---|---|
| positive regulation of leukotriene production involved in inflammatory response | |
| positive regulation of coagulation | |
| positive regulation of interleukin-8 production | |
| positive regulation of blood coagulation | |
| negative regulation of fibrinolysis | |
| negative regulation of blood coagulation | |
| fibrinolysis | |
| blood coagulation | |
| platelet activation | |
| angiogenesis | |
| regulation of angiogenesis | |
| positive regulation of angiogenesis | |
| negative regulation of vascular wound healing | |
| tissue regeneration | |
| chronological cell aging | |
| negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | |
| regulation of receptor activity | |
| transforming growth factor beta receptor signaling pathway | |
| platelet degranulation | |
| negative regulation of smooth muscle cell-matrix adhesion | |
| negative regulation of cell adhesion mediated by integrin | |
| negative regulation of cell migration | |
| negative regulation of smooth muscle cell migration | |
| negative regulation of endothelial cell apoptotic process | |
| extracellular matrix organization | |
| regulation of cell proliferation | |
| response to reactive oxygen species | |
| cellular response to lipopolysaccharide | |
| response to cytokine | |
| response to estrogen | |
| response to glucocorticoid | |
| response to hyperoxia | |
| defense response to Gram-negative bacterium | |
| positive regulation of inflammatory response | |
| wound healing | |
| negative regulation of wound healing | |
| cellular response to gravity | |
| positive regulation of transcription from RNA polymerase II promoter | |
| positive regulation of receptor-mediated endocytosis | |
| negative regulation of proteolysis | |
| negative regulation of plasminogen activation | |
| regulation of proteolysis | |
| negative regulation of peptidase activity | |
| negative regulation of endopeptidase activity | |
| transcription, DNA-templated | |
| transcription initiation from RNA polymerase II promoter | |
| gene expression | |
| glucose homeostasis |
| Pathway | Proliferative Diabetic Retinopathy |
|---|---|
| Role of Hexosamine Pathway in Diabetic Microangiopathy | |
| Proteins Involved in Pathogenesis of Insulin Resistance | |
| Proteins Involved in Pathogenesis of Diabetes Mellitus Type 2 | |
| Role of Advanced Glycation End Products Pathway in Diabetic Microangiopathy | |
| Peripheral Tissue Microangiopathy in Insulin Resistance | |
| Thyroid Hormones in Adipose Tissue Metabolism | |
| Proteins Involved in Pathogenesis of Atherosclerosis | |
| RAGE/AGER and S100 Proteins in Cardiovascular Injury in Atherosclerosis | |
| Endothelial Cell Dysfunction in Pulmonary Arterial Hypertension | |
| Proteins Involved in Pathogenesis of Pulmonary Hypertension | |
| Proteins Involved in Pathogenesis of Neuroblastoma | |
| Proteins Involved in Pathogenesis of Polycystic Ovary Syndrome | |
| Proteins Involved in Pathogenesis of Gout | |
| Proteins Involved in Pathogenesis of Myocardial Ischemia | |
| Role of Scavenger Receptor OLR1 in Inflammation-Related Endothelial Dysfunction in Atherosclerosis | |
| TGFB3-TGFBR2 Expression Targets | |
| TGFB1-TGFBR2 Expression Targets | |
| BMP7-ACVR2 Expression Targets | |
| INHBA-ACVR2/ACVR1 Expression Targets | |
| BMP2-BMPR2 Expression Targets | |
| WNT1 Expression Targets | |
| TLR4/NF-kB/IRF Expression Targets | |
| TGFB3-TGFBR1 Expression Targets | |
| BDNF Expression Targets | |
| CD40LG/NF-kB/ELK-SRF/CREB/NFATC Expression Targets | |
| LTA Expression Targets | |
| TNFSF14 Expression Targets | |
| TNF/STAT Expression Targets | |
| TNF/TP53/ATF Expression Targets | |
| CD40LG/ATF2/AP-1/TP53/E2F Expression Targets | |
| CD40LG/STAT Expression Targets | |
| Fibrinogen Expression Targets | |
| IL6 Expression Targets | |
| IL2 Expression Targets | |
| LIF Expression Targets | |
| Thrombopoietin/STAT Expression Targets | |
| Erythropoietin/STAT Expression Targets | |
| GH1-GHR/NF-kB/ELK-SRF/MYC Expression Targets | |
| GH1-GHR/STAT Expression Targets | |
| PRL-GHR/NF-kB/ELK-SRF/MYC Expression Targets | |
| PRL-GHR/STAT Expression Targets | |
| GH1-PRLR Expression Targets | |
| PRL-PRLR Expression Targets | |
| IFNG-IFNR Expression Targets | |
| IFNA1-IFNR Expression Targets | |
| OSM-OSMR Expression Targets | |
| Leptin/ELK-SRF Expression Targets | |
| Leptin/STAT Expression Targets | |
| CXCL12 Expression Targets | |
| EGF/HIF1A Expression Targets | |
| EGF/TP53 Expression Targets | |
| HBEGF/STAT Expression Targets | |
| HBEGF/AP-1/ATF Expression Targets | |
| HBEGF/EP300/ETS/ETV/SP1 Expression Targets | |
| HBEGF/HIF1A Expression Targets | |
| HBEGF/TP53 Expression Targets | |
| FGF1/STAT Expression Targets | |
| Thrombopoietin/AP-1/CREB/CREBBP/MYC Expression Targets | |
| HBEGF/CREB/MYC Expression Targets | |
| FGF1/AP-1/CREB/ELK-SRF/MYC Expression Targets | |
| FGF4/AP-1/MYC Expression Targets | |
| F2 -> AP-1/CREB/ELK-SRF/SP1 Expression Targets | |
| Thromboxane A2 Expression Targets | |
| F2 -> STAT1/NF-kB Expression Targets | |
| Prostaglandin F Expression Targets | |
| AVP/Gq -> STAT Expression Targets | |
| AVP/Gq -> CREB/ELK-SRF/AP-1/EGR Expression Targets | |
| Morphine Expression Targets | |
| S1P Expression Targets | |
| TAC1 Expression Targets | |
| PGE1 Expression Targets | |
| Noradrenaline/Gs Expression Targets | |
| AVP/Gs -> STAT Expression Targets | |
| AVP/Gs -> CREB/ELK-SRF/AP-1/EGR Expression Targets | |
| Noreadrenaline/Gq Expression Targets | |
| IFNA1/Gq Expression Targets | |
| EDN1 Expression Targets | |
| AGT/TP53 Expression Targets | |
| FGF2/AP-1/CREB/CREBBP/ELK-SRF/MYC Expression Targets | |
| HGF/STAT Expression Targets | |
| IGF1/STAT Expression Targets | |
| Insulin/ELK-SRF/HIF1A/MYC/SREBF Expression Targets | |
| Insulin/STAT Expression Targets | |
| FGF2/STAT Expression Targets | |
| IL1A Expression Targets | |
| INHBA-ACVR2/BMPR Expression Targets | |
| TGFB1-TGFBR1 Expression Targets | |
| TNF/NF-kB Expression Targets | |
| PAF Expression Targets | |
| AGT/CREB Expression Targets | |
| EGF/AP-1/ATF Expression Targets | |
| EGF/CREB/CREBBP/ELK-SRF/MYC Expression Targets | |
| EGF/MEF/MYOD/NFATC Expression Targets | |
| EGF/STAT Expression Targets | |
| HGF/AP-1/CREB/ELK-SRF/MYC Expression Targets | |
| IGF1/ELK-SRF/HIF1A/MYC/SREBF Expression Targets | |
| IGF1/MEF/MYOD/MYOG Expression Targets | |
| IL1B/NO Expression Targets | |
| Insulin/CEBPA/CTNNB/FOXA/FOXO Expression Targets | |
| Insulin/MEF/MYOD Expression Targets | |
| PDGF/AP-1/CREB/CREBBP/MYC Expression Targets | |
| PDGF/STAT Expression Targets | |
| TGFB1-ACVRL1 Expression Targets | |
| TGFB1-TGFBR1/AP-1 Expression Targets | |
| TLR4/AP-1 Expression Targets | |
| TNF/AP-1 Expression Targets | |
| IL1B Expression Targets | |
| EGF/CTNN Expression Targets | |
| fibrinolysis pathway |
| Group | positive regulation of monocyte chemotaxis |
|---|---|
| positive regulation of leukotriene production involved in inflammatory response | |
| positive regulation of coagulation | |
| positive regulation of interleukin-8 production | |
| positive regulation of blood coagulation | |
| negative regulation of fibrinolysis | |
| negative regulation of blood coagulation | |
| fibrinolysis | |
| blood coagulation | |
| platelet activation | |
| angiogenesis | |
| regulation of angiogenesis | |
| positive regulation of angiogenesis | |
| negative regulation of vascular wound healing | |
| tissue regeneration | |
| chronological cell aging | |
| negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | |
| regulation of receptor activity | |
| transforming growth factor beta receptor signaling pathway | |
| platelet degranulation | |
| negative regulation of smooth muscle cell-matrix adhesion | |
| negative regulation of cell adhesion mediated by integrin | |
| negative regulation of cell migration | |
| negative regulation of smooth muscle cell migration | |
| negative regulation of endothelial cell apoptotic process | |
| extracellular matrix organization | |
| regulation of cell proliferation | |
| response to reactive oxygen species | |
| cellular response to lipopolysaccharide | |
| response to cytokine | |
| response to estrogen | |
| response to glucocorticoid | |
| response to hyperoxia | |
| defense response to Gram-negative bacterium | |
| positive regulation of inflammatory response | |
| wound healing | |
| negative regulation of wound healing | |
| cellular response to gravity | |
| positive regulation of transcription from RNA polymerase II promoter | |
| positive regulation of receptor-mediated endocytosis | |
| negative regulation of proteolysis | |
| negative regulation of plasminogen activation | |
| regulation of proteolysis | |
| peptidase inhibitor activity | |
| serine-type endopeptidase inhibitor activity | |
| negative regulation of peptidase activity | |
| negative regulation of endopeptidase activity | |
| transcription, DNA-templated | |
| transcription initiation from RNA polymerase II promoter | |
| gene expression | |
| glucose homeostasis | |
| receptor binding | |
| protease binding | |
| extracellular matrix | |
| extracellular region | |
| platelet alpha granule lumen | |
| plasma membrane | |
| extracellular space | |
| Proteins Involved in Pathogenesis of Body Weight Change Caused by Hypothyroidism | |
| Genes Associated with Systemic Lupus Erythematosus | |
| Secreted proteins | |
| Biofluids assayable substances |
| LocusLink ID | 5054 |
|---|---|
| 18787 | |
| 24617 |
| Cell Localization | Secreted |
|---|
| GO ID | 0002020 |
|---|---|
| 0005102 | |
| 0004867 | |
| 0001525 | |
| 0007596 | |
| 0071222 | |
| 0001300 | |
| 0050829 | |
| 0030198 | |
| 0042730 | |
| 0010467 | |
| 0030195 | |
| 0033629 | |
| 0030336 | |
| 0010951 | |
| 2000352 | |
| 1902042 | |
| 0051918 | |
| 0010757 | |
| 0014912 | |
| 2000098 | |
| 0061044 | |
| 0061045 | |
| 0030168 | |
| 0002576 | |
| 0045766 | |
| 0030194 | |
| 0050729 | |
| 0032757 | |
| 0035491 | |
| 0090026 | |
| 0048260 | |
| 0045944 | |
| 0042127 | |
| 0010469 | |
| 0006367 | |
| 0006351 | |
| 0007179 | |
| 0031012 | |
| 0005576 | |
| 0005615 | |
| 0005886 | |
| 0031093 | |
| 0030414 | |
| 0010466 | |
| 0050820 | |
| 0045765 | |
| 0042060 | |
| 0071258 | |
| 0042593 | |
| 0045861 | |
| 0030162 | |
| 0034097 | |
| 0043627 | |
| 0051384 | |
| 0055093 | |
| 0000302 | |
| 0042246 |
| Alias | PAI |
|---|---|
| PAI1 | |
| PAI-1 | |
| PLANH1 | |
| plasminogen activator inhibitor 1 | |
| serpin E1 | |
| endothelial plasminogen activator inhibitor | |
| serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | |
| plasminogen activator inhibitor, type I | |
| nexin, plasminogen activator inhibitor type 1 | |
| serine (or cysteine) proteinase inhibitor, clade E, member 1 | |
| Plasminogen activator inhibitor-1 precursor (PAI-1) (Endothelial plasminogen activator inhibitor) (PAI) | |
| PAI1A | |
| Planh | |
| Pai1aa | |
| RATPAI1A | |
| serine (or cysteine) proteinase inhibitor, member 1 | |
| serine (or cysteine) peptidase inhibitor, clade E, member 1 | |
| serine (or cysteine) protease inhibitor, member I | |
| serine (or cysteine) proteinase inhibitor, clade E member I | |
| serine (or cysteine) proteinase inhibitor, member I | |
| serine (or cysteine)ase inhibitor, clade E, member 1 | |
| serine (or cysteine)ase inhibitor, clade E, member I | |
| serine (or cysteine)ase inhibitor, member 1 | |
| serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | |
| Serpine I | |
| SERPINE1 | |
| mesosecrin | |
| urokinase inhibitor PAI-1 | |
| serine (or cysteine) protease inhibitor, member 1 | |
| serine (or cysteine)ase inhibitor, member I | |
| LOC231790 | |
| serine (or cysteine) protease inhibitor, clade E, member 1 | |
| PAI I | |
| PLANH I | |
| serine (or cysteine) protease inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | |
| plasminogen activation inhibitor-1 | |
| serine (or cysteine) protease inhibitor, clade E member I | |
| Plasminogen activator inhibitor-1 precursor (PAI-1) (Endothelial plasminogen activator inhibitor) | |
| plasminogen activator inhibitor-1 |
| Mouse chromosome position | 5 |
|---|
| OMIM ID | 173360 |
|---|---|
| 613329 |
| Rat chromosome position | 12q11-q12 |
|---|
| Hugo ID | 8583 |
|---|
| Human chromosome position | 7q22.1 |
|---|
| Swiss-Prot Accession | P05121 |
|---|---|
| G5E899 | |
| P22777 | |
| P20961 | |
| B7Z4S0 | |
| F8WD53 |
| PIR ID | A28107 |
|---|---|
| A35032 |
| Unigene ID | Hs.414795 |
|---|---|
| Hs.713079 | |
| Hs.741440 | |
| Mm.250422 | |
| Rn.29367 |
| KEGG ID | hsa:5054 |
|---|---|
| mmu:18787 | |
| rno:24617 |
| Swiss-Prot ID | PAI1_HUMAN |
|---|---|
| PAI1_RAT |
| Ensembl ID | ENSG00000106366 |
|---|---|
| ENSP00000223095 | |
| ENST00000223095 | |
| ENSP00000396766 | |
| ENST00000445463 | |
| ENSMUSG00000037411 | |
| ENSMUSP00000039586 | |
| ENSMUST00000041388 | |
| ENSRNOG00000001414 | |
| ENSRNOP00000001916 | |
| ENSRNOT00000001916 |
| Homologene ID | 68070 |
|---|
| Organism | Homo sapiens |
|---|---|
| Mus musculus | |
| Rattus norvegicus |
| MGI ID | 97608 |
|---|
| RGD ID | 3249 |
|---|
| MedScan ID | 5054 |
|---|